Tirzepatide – Breaking body weight barriers in type 2 diabetes

Combination of man 1,2,3 - image for home page (300x165px)

International experts discuss their clinical experience with Tirzepatide - a GIP and GLP-1 RA now available in South Africa for obese T2DM patient care

Learning objectives

You will learn:

  • The associations between obesity, type 2 diabetes (T2DM) and cardiovascular disease (CVD)
  • Metabolic and clinical effects of weight loss in the patient with T2DM and/or CVD
  • The different mechanisms of action of tirzepatide (TZP), a novel incretin therapy for the
    management of T2DM
  • An overview of clinical trial evidence and real-world experience with TZP, across the spectrum
    of T2DM.

To access this module, please register or login: